Anaplastic Lymphoma Kinase Inhibitors Market – Actionable Research on COVID-19 | High Specificity of ALK Inhibitors to Boost the Market Growth | Technavio
October 7, 2020LONDON–(BUSINESS WIRE)–#AnaplasticLymphomaKinaseALKInhibitorsMarket–The global anaplastic lymphoma kinase inhibitors market size is poised to grow by USD 2.96 billion during 2020-2024, progressing at a CAGR of over 20% throughout the forecast period, according to the latest report by Technavio. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. The report also provides the market impact and new opportunities created due to the COVID-19 pandemic. Download a Free Sample of REPORT with COVID-19 Crisis and Recovery Analysis
Despite the availability of several approved therapies for the treatment of advanced and recurring carcinomas, the adverse effects of these treatments may reduce patient adherence. Anaplastic lymphoma kinase has emerged as a promising solution for NSCLC treatments as these drugs work on the target directly with higher efficacy than conventional therapies. ALK inhibitors can act on tumors with ALK variations such as echinoderm microtubule associated protein like 4 (EML4)-ALK translocations. Strong research and development and positive clinical trials of late-stage molecules will further boost the popularity of ALK inhibitors among medical practitioners and patients. The high target affinity and specificity of ALK inhibitors will be one of the significant factors driving the growth of the market.
Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio’s SUBSCRIPTION platform
Report Highlights:
- The major anaplastic lymphoma kinase inhibitors market growth came from second-generation ALK inhibitors segment. The high prevalence of lung cancer, strong pipeline development, and recent approvals are some of the significant factors driving the growth of the anaplastic lymphoma kinase market in this segment. Market growth in this segment will be slower than the growth of the market in the first-generation and third generation ALK inhibitors segment.
- North America was the largest anaplastic lymphoma kinase inhibitors market in 2019, and the region will offer several growth opportunities to market vendors during the forecast period. Factors such as the increasing prevalence of lung cancer and the high sales of approved ALK inhibitors will significantly drive anaplastic lymphoma kinase inhibitors market growth in this region over the forecast period. (Read more…)
- The global anaplastic lymphoma kinase inhibitors market is concentrated. AstraZeneca Plc, Betta Pharmaceuticals Co. Ltd., Bio-Techne Corp., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck KGaA, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and Turning Point Therapeutics Inc. are some of the major market participants. To help clients improve their market position, this anaplastic lymphoma kinase inhibitors market forecast report provides a detailed analysis of the market leaders.
- As the business impact of COVID-19 spreads, the global anaplastic lymphoma kinase inhibitors market 2020-2024 is expected to have Neutral and At par growth. As the pandemic spreads in some regions and plateaus in other regions, we revaluate the impact on businesses and update our report forecasts.
Read the full report here: https://www.technavio.com/report/report/anaplastic-lymphoma-kinase-alk-inhibitors-market-industry-analysis
Approvals of Combination Therapies and the Extension of the Application of ALK Inhibitors will be a Key Market Trend
The high efficacy of ALK inhibitors in the treatment of NSCLC has encouraged vendors to perform additional clinical trials for expanding its application to various other oncology indications. Vendors are also studying the effects of ALK inhibitors in combination therapies to enhance their efficacy in cancer treatment. The approvals of such combination therapies and the extension of the application of ALK inhibitors will broaden its customer base. Such factors will consequently boost ALK inhibitors market growth.
Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report
Anaplastic lymphoma kinase inhibitors market 2020-2024: Key Highlights
- CAGR of the market during the forecast period 2020-2024
- Detailed information on factors that will assist anaplastic lymphoma kinase inhibitors market growth during the next five years
- Estimation of the anaplastic lymphoma kinase inhibitors market size and its contribution to the parent market
- Predictions on upcoming trends and changes in consumer behavior
- The growth of the anaplastic lymphoma kinase inhibitors market
- Analysis of the market’s competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of anaplastic lymphoma kinase inhibitors market vendors
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
View market snapshot before purchasing
Executive Summary
Market Landscape
- Market ecosystem
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2019
- Market outlook: Forecast for 2019 – 2024
Five Forces Analysis
- Five forces summary
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Type
- Market segments
- Comparison by Type
- Second-generation ALK inhibitors – Market size and forecast 2019-2024
- First-generation ALK inhibitors – Market size and forecast 2019-2024
- Third-generation ALK inhibitors – Market size and forecast 2019-2024
- Market opportunity by Type
Customer landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America – Market size and forecast 2019-2024
- Europe – Market size and forecast 2019-2024
- Asia – Market size and forecast 2019-2024
- ROW – Market size and forecast 2019-2024
- Key leading countries
- Market opportunity by geography
- Volume drivers – Demand led growth
- Volume drivers – External factors
- Market challenges
- Market trends
Vendor Landscape
- Overview
- Vendor landscape
- Landscape disruption
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- AstraZeneca Plc
- Betta Pharmaceuticals Co. Ltd.
- Bio-Techne Corp.
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Merck KGaA
- Novartis AG
- Pfizer Inc.
- Takeda Pharmaceutical Co. Ltd.
- Turning Point Therapeutics Inc.
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
Anaplastic Lymphoma Kinase Inhibitors Market – Actionable Research on COVID-19 | High Specificity of ALK Inhibitors to Boost the Market Growth | Technavio
October 7, 2020LONDON–(BUSINESS WIRE)–#AnaplasticLymphomaKinaseALKInhibitorsMarket–The global anaplastic lymphoma kinase inhibitors market size is poised to grow by USD 2.96 billion during 2020-2024, progressing at a CAGR of over 20% throughout the forecast period, according to the latest report by Technavio. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. The report also provides the market impact and new opportunities created due to the COVID-19 pandemic. Download a Free Sample of REPORT with COVID-19 Crisis and Recovery Analysis
Despite the availability of several approved therapies for the treatment of advanced and recurring carcinomas, the adverse effects of these treatments may reduce patient adherence. Anaplastic lymphoma kinase has emerged as a promising solution for NSCLC treatments as these drugs work on the target directly with higher efficacy than conventional therapies. ALK inhibitors can act on tumors with ALK variations such as echinoderm microtubule associated protein like 4 (EML4)-ALK translocations. Strong research and development and positive clinical trials of late-stage molecules will further boost the popularity of ALK inhibitors among medical practitioners and patients. The high target affinity and specificity of ALK inhibitors will be one of the significant factors driving the growth of the market.
Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio’s SUBSCRIPTION platform
Report Highlights:
- The major anaplastic lymphoma kinase inhibitors market growth came from second-generation ALK inhibitors segment. The high prevalence of lung cancer, strong pipeline development, and recent approvals are some of the significant factors driving the growth of the anaplastic lymphoma kinase market in this segment. Market growth in this segment will be slower than the growth of the market in the first-generation and third generation ALK inhibitors segment.
- North America was the largest anaplastic lymphoma kinase inhibitors market in 2019, and the region will offer several growth opportunities to market vendors during the forecast period. Factors such as the increasing prevalence of lung cancer and the high sales of approved ALK inhibitors will significantly drive anaplastic lymphoma kinase inhibitors market growth in this region over the forecast period. (Read more…)
- The global anaplastic lymphoma kinase inhibitors market is concentrated. AstraZeneca Plc, Betta Pharmaceuticals Co. Ltd., Bio-Techne Corp., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck KGaA, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and Turning Point Therapeutics Inc. are some of the major market participants. To help clients improve their market position, this anaplastic lymphoma kinase inhibitors market forecast report provides a detailed analysis of the market leaders.
- As the business impact of COVID-19 spreads, the global anaplastic lymphoma kinase inhibitors market 2020-2024 is expected to have Neutral and At par growth. As the pandemic spreads in some regions and plateaus in other regions, we revaluate the impact on businesses and update our report forecasts.
Read the full report here: https://www.technavio.com/report/report/anaplastic-lymphoma-kinase-alk-inhibitors-market-industry-analysis
Approvals of Combination Therapies and the Extension of the Application of ALK Inhibitors will be a Key Market Trend
The high efficacy of ALK inhibitors in the treatment of NSCLC has encouraged vendors to perform additional clinical trials for expanding its application to various other oncology indications. Vendors are also studying the effects of ALK inhibitors in combination therapies to enhance their efficacy in cancer treatment. The approvals of such combination therapies and the extension of the application of ALK inhibitors will broaden its customer base. Such factors will consequently boost ALK inhibitors market growth.
Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report
Anaplastic lymphoma kinase inhibitors market 2020-2024: Key Highlights
- CAGR of the market during the forecast period 2020-2024
- Detailed information on factors that will assist anaplastic lymphoma kinase inhibitors market growth during the next five years
- Estimation of the anaplastic lymphoma kinase inhibitors market size and its contribution to the parent market
- Predictions on upcoming trends and changes in consumer behavior
- The growth of the anaplastic lymphoma kinase inhibitors market
- Analysis of the market’s competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of anaplastic lymphoma kinase inhibitors market vendors
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
View market snapshot before purchasing
Executive Summary
Market Landscape
- Market ecosystem
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2019
- Market outlook: Forecast for 2019 – 2024
Five Forces Analysis
- Five forces summary
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Type
- Market segments
- Comparison by Type
- Second-generation ALK inhibitors – Market size and forecast 2019-2024
- First-generation ALK inhibitors – Market size and forecast 2019-2024
- Third-generation ALK inhibitors – Market size and forecast 2019-2024
- Market opportunity by Type
Customer landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America – Market size and forecast 2019-2024
- Europe – Market size and forecast 2019-2024
- Asia – Market size and forecast 2019-2024
- ROW – Market size and forecast 2019-2024
- Key leading countries
- Market opportunity by geography
- Volume drivers – Demand led growth
- Volume drivers – External factors
- Market challenges
- Market trends
Vendor Landscape
- Overview
- Vendor landscape
- Landscape disruption
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- AstraZeneca Plc
- Betta Pharmaceuticals Co. Ltd.
- Bio-Techne Corp.
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Merck KGaA
- Novartis AG
- Pfizer Inc.
- Takeda Pharmaceutical Co. Ltd.
- Turning Point Therapeutics Inc.
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
Anaplastic Lymphoma Kinase Inhibitors Market – Actionable Research on COVID-19 | High Specificity of ALK Inhibitors to Boost the Market Growth | Technavio
October 7, 2020LONDON–(BUSINESS WIRE)–#AnaplasticLymphomaKinaseALKInhibitorsMarket–The global anaplastic lymphoma kinase inhibitors market size is poised to grow by USD 2.96 billion during 2020-2024, progressing at a CAGR of over 20% throughout the forecast period, according to the latest report by Technavio. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. The report also provides the market impact and new opportunities created due to the COVID-19 pandemic. Download a Free Sample of REPORT with COVID-19 Crisis and Recovery Analysis
Despite the availability of several approved therapies for the treatment of advanced and recurring carcinomas, the adverse effects of these treatments may reduce patient adherence. Anaplastic lymphoma kinase has emerged as a promising solution for NSCLC treatments as these drugs work on the target directly with higher efficacy than conventional therapies. ALK inhibitors can act on tumors with ALK variations such as echinoderm microtubule associated protein like 4 (EML4)-ALK translocations. Strong research and development and positive clinical trials of late-stage molecules will further boost the popularity of ALK inhibitors among medical practitioners and patients. The high target affinity and specificity of ALK inhibitors will be one of the significant factors driving the growth of the market.
Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio’s SUBSCRIPTION platform
Report Highlights:
- The major anaplastic lymphoma kinase inhibitors market growth came from second-generation ALK inhibitors segment. The high prevalence of lung cancer, strong pipeline development, and recent approvals are some of the significant factors driving the growth of the anaplastic lymphoma kinase market in this segment. Market growth in this segment will be slower than the growth of the market in the first-generation and third generation ALK inhibitors segment.
- North America was the largest anaplastic lymphoma kinase inhibitors market in 2019, and the region will offer several growth opportunities to market vendors during the forecast period. Factors such as the increasing prevalence of lung cancer and the high sales of approved ALK inhibitors will significantly drive anaplastic lymphoma kinase inhibitors market growth in this region over the forecast period. (Read more…)
- The global anaplastic lymphoma kinase inhibitors market is concentrated. AstraZeneca Plc, Betta Pharmaceuticals Co. Ltd., Bio-Techne Corp., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck KGaA, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and Turning Point Therapeutics Inc. are some of the major market participants. To help clients improve their market position, this anaplastic lymphoma kinase inhibitors market forecast report provides a detailed analysis of the market leaders.
- As the business impact of COVID-19 spreads, the global anaplastic lymphoma kinase inhibitors market 2020-2024 is expected to have Neutral and At par growth. As the pandemic spreads in some regions and plateaus in other regions, we revaluate the impact on businesses and update our report forecasts.
Read the full report here: https://www.technavio.com/report/report/anaplastic-lymphoma-kinase-alk-inhibitors-market-industry-analysis
Approvals of Combination Therapies and the Extension of the Application of ALK Inhibitors will be a Key Market Trend
The high efficacy of ALK inhibitors in the treatment of NSCLC has encouraged vendors to perform additional clinical trials for expanding its application to various other oncology indications. Vendors are also studying the effects of ALK inhibitors in combination therapies to enhance their efficacy in cancer treatment. The approvals of such combination therapies and the extension of the application of ALK inhibitors will broaden its customer base. Such factors will consequently boost ALK inhibitors market growth.
Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report
Anaplastic lymphoma kinase inhibitors market 2020-2024: Key Highlights
- CAGR of the market during the forecast period 2020-2024
- Detailed information on factors that will assist anaplastic lymphoma kinase inhibitors market growth during the next five years
- Estimation of the anaplastic lymphoma kinase inhibitors market size and its contribution to the parent market
- Predictions on upcoming trends and changes in consumer behavior
- The growth of the anaplastic lymphoma kinase inhibitors market
- Analysis of the market’s competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of anaplastic lymphoma kinase inhibitors market vendors
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
View market snapshot before purchasing
Executive Summary
Market Landscape
- Market ecosystem
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2019
- Market outlook: Forecast for 2019 – 2024
Five Forces Analysis
- Five forces summary
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Type
- Market segments
- Comparison by Type
- Second-generation ALK inhibitors – Market size and forecast 2019-2024
- First-generation ALK inhibitors – Market size and forecast 2019-2024
- Third-generation ALK inhibitors – Market size and forecast 2019-2024
- Market opportunity by Type
Customer landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America – Market size and forecast 2019-2024
- Europe – Market size and forecast 2019-2024
- Asia – Market size and forecast 2019-2024
- ROW – Market size and forecast 2019-2024
- Key leading countries
- Market opportunity by geography
- Volume drivers – Demand led growth
- Volume drivers – External factors
- Market challenges
- Market trends
Vendor Landscape
- Overview
- Vendor landscape
- Landscape disruption
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- AstraZeneca Plc
- Betta Pharmaceuticals Co. Ltd.
- Bio-Techne Corp.
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Merck KGaA
- Novartis AG
- Pfizer Inc.
- Takeda Pharmaceutical Co. Ltd.
- Turning Point Therapeutics Inc.
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/